COVID-19 and the Rheumatologist: The Good, the Bad and the Ugly

We end the year with Leonard Calabrese, DO, giving us a summary of what we’ve learned about COVID-19 from the perspective of a rheumatologist.

Brought to you by GSK. Considering a treatment change for patients with active SLE? Learn about a treatment option for your patients at treatfortodayandtomorrow.com.

• Intro :10
• Calabrese introduction :24
• In this episode :43
• Nobody has complete control of the literature on COVID-19 1:39
• What was ugly about COVID-19? 2:16
• What was bad about COVID-19? 4:05
• What good came from the COVID-19 pandemic? 7:07

Brought to you by GSK. Consider the long-term impact of disease activity flares and corticosteroid use on patients with active SLE. Learn more now at treatfortodayandtomorrow.com.

• The good things continued 10:20
• JAK inhibitors 11:30
• The best outcomes: Vaccines 14:15
• Pertinent questions for the rheumatology community 16:45
• Recap 20:12
• Conclusion 21:41

Disclosures: Calabrese reports no relevant financial disclosures.

We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum